智通财经APP讯，希玛医疗(03309)发布公告，截至2024年12月31日止年度集团预期公司权益持有人应占溢利(经调整应占纯利)将介乎5000万港元至6000万港元(2023财政年度：6200万港元)，撇除下述减值亏损的影响，除利息、税项、折旧及摊销前盈利(经调整EBITDA)将约为3亿港元(2023财政年度：3.44亿港元)。由于集团医院及诊所的商誉、物业、厂房及设备以及使用权资产预期取得若干减值介乎约1.95亿港元至2.15亿港元，集团预期取得公司权益持有人应占亏损介乎约1.3亿港元至1.6亿港元(2023财政年度：溢利6200万港元)。以2024财政年度的收益而言，预期集团于2024财政年度的收益约19.00亿港元，而2023财政年度的收益为19.24亿港元。
公告称，减值亏损乃由于竞争激烈及2024年整体消费意欲减弱，导致若干医院及诊所的表现逊于预期。上述减值为一次性非现金开支，不会对集团的整体营运造成任何影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.